Compared to Estimates, Abbott (ABT) Q1 Earnings: A Look at Key Metrics

Core Insights - Abbott reported $10.36 billion in revenue for Q1 2025, a 4% year-over-year increase, with an EPS of$ 1.09 compared to $0.98 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of$ 10.42 billion, resulting in a surprise of -0.56%, while the EPS exceeded expectations by 1.87% [1] Financial Performance Metrics - Net sales in Nutrition - International reached $1.19 billion, matching the average estimate, with a year-over-year change of +0.1% [4] - Net sales in Nutrition - U.S. were$ 955 million, surpassing the estimated $925.35 million, reflecting an 8.8% increase year-over-year [4] - Net sales in Diagnostics - U.S. totaled$ 871 million, below the estimated $927.13 million, showing a year-over-year decline of -6.4% [4] - Net sales in Diagnostics - International were$ 1.18 billion, compared to the estimated $1.28 billion, indicating a -7.8% year-over-year change [4] - Total net sales in Nutrition amounted to$ 2.15 billion, exceeding the estimated $2.12 billion, with a +3.8% change year-over-year [4] - Medical Devices - Diabetes Care generated$ 1.83 billion, slightly above the estimated $1.82 billion, marking a +16.4% year-over-year increase [4] - Total net sales in Diagnostics were$ 2.05 billion, below the estimated $2.19 billion, reflecting a -7.2% year-over-year change [4] - Established Pharmaceuticals net sales reached$ 1.26 billion, slightly above the estimated $1.23 billion, with a +2.8% year-over-year change [4] - Medical Devices - Vascular total sales were$ 710 million, exceeding the estimated $704.85 million, with a +3.1% year-over-year change [4] - Medical Devices - Neuromodulation total sales were$ 228 million, slightly below the estimated $235.53 million, with a +0.9% year-over-year change [4] - Medical Devices - Structural Heart total sales were$ 577 million, below the estimated $592.77 million, reflecting a +12% year-over-year change [4] - Medical Devices - Heart Failure total sales were$ 339 million, surpassing the estimated $325.77 million, with an +11.2% year-over-year change [4] Stock Performance - Abbott's shares returned -0.1% over the past month, compared to the Zacks S&P 500 composite's -4.2% change, indicating relative stability [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]